Acest rezumat localizat oferă o prezentare orientată pe dovezi pentru acest subiect. Conținutul extins de mai jos este păstrat în limba engleză pentru consistență editorială.

Selank vs Semax: Nootropic Peptide Research Comparison

Selank and Semax are two synthetic heptapeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, both used as pharmaceutical agents in Russia for cognitive and neurological applications. Despite sharing size and overlapping nootropic framing, they derive from entirely different parent molecules and produce notably different neurochemical profiles.

Side-by-Side

Different Origins, Different Profiles

Selank is built around the tuftsin backbone (Thr-Lys-Pro-Arg), a naturally occurring tetrapeptide released from IgG in the spleen. Tuftsin is a well-characterized immunostimulant. The Selank molecule extends tuftsin with a stabilizing Pro-Gly-Pro tail that enhances metabolic stability and blood-brain barrier penetration. This immune-system origin explains why Selank exhibits pronounced effects on GABAergic and serotonergic neurotransmission — the immune and nervous systems share bidirectional communication via these pathways. Research has shown Selank increases GABA-A receptor subunit gene expression in hippocampus and modulates serotonin metabolism, producing measurable anxiolytic effects in elevated plus maze and open field paradigms.

Semax was engineered from the ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) — the minimal neurotrophic sequence of adrenocorticotropic hormone without steroidogenic effects. This stress-hormone lineage explains its stimulatory profile. Semax upregulates BDNF (key to synaptic plasticity and memory), enhances dopaminergic and noradrenergic signaling (substrates of attention and executive function), and transcriptomic studies show modulation of 100+ genes related to neuronal survival and synaptic transmission within hours of administration.

Anxiolytic vs Stimulatory: Choosing the Right Tool

Selank fits experimental models where anxiolytic or stress-resilience endpoints matter, or where the immune-anxiety link is the hypothesis. It reduces anxiety-like behaviors without the sedation, motor impairment, or dependence profile of benzodiazepines — a clean anxiolytic profile through endogenous neurotransmitter modulation rather than direct receptor agonism.

Semax fits paradigms focused on learning, memory, attention, and neuroprotection. It has been studied in cerebral ischemia models, with protective effects on neuronal survival and functional recovery likely mediated through BDNF and anti-apoptotic signaling. Behaviorally, it improves passive avoidance learning, spatial navigation, and working memory — stimulatory in character but without sympathomimetic side-effect profiles of amphetamine-class compounds.

The two are not mutually exclusive; some protocols investigate them in combination to pair anxiolytic modulation with nootropic enhancement.

Bottom Line

Selank is the anxiolytic peptide with a nootropic overlay. Semax is the stimulatory nootropic with neuroprotective properties. The choice should follow endpoint, not brand: GABA/serotonin mechanisms answer different questions than dopamine/BDNF mechanisms.

Educational content only. Not medical advice.